|
1
|
McGowan JV, Chung R, Maulik A, Piotrowska
I, Walker JM and Yellon DM: Anthracycline chemotherapy and
cardiotoxicity. Cardiovasc Drugs Ther. 31:63–75. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Nebigil CG and Désaubry L: Updates in
anthracycline-mediated cardiotoxicity. Front Pharmacol. 9:12622018.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Swain SM, Whaley FS and Ewer MS:
Congestive heart failure in patients treated with doxorubicin: A
retrospective analysis of three trials. Cancer. 97:2869–2879. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Ewer MS and Ewer SM: Cardiotoxicity of
anticancer treatments: What the cardiologist needs to know. Nat Rev
Cardiol. 7:564–575. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Jungsuwadee P: Doxorubicin-induced
cardiomyopathy: An update beyond oxidative stress and myocardial
cell death. Cardiovasc Reg Med. 3:e11272016.
|
|
6
|
Ohtani K, Fujino T, Ide T, Funakoshi K,
Sakamoto I, Hiasa KI, Higo T, Kamezaki K, Akashi K and Tsutsui H:
Recovery from left ventricular dysfunction was associated with the
early introduction of heart failure medical treatment in cancer
patients with anthracycline-induced cardiotoxicity. Clin Res
Cardiol. 108:600–611. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Raj S, Franco VI and Lipshultz SE:
Anthracycline-induced cardiotoxicity: A review of pathophysiology,
diagnosis, and treatment. Curr Treat Options Cardiovasc Med.
16:3152014. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Zamorano JL, Lancellotti P, Muñoz DR,
Aboyans V, Asteggiano R, Galderisi M, Habib G, Lenihan DJ, Lip GY,
Lyon AR, et al: 2016 ESC position paper on cancer treatments and
cardiovascular toxicity developed under the auspices of the ESC
committee for practice guidelines. Kardiol Pol. 74:1193–1233.
2016.(In Polish). View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Glass CK and Mitchell RN: Winning the
battle, but losing the war: Mechanisms and morphology of
cancer-therapy-associated cardiovascular toxicity. Cardiovasc
Pathol. 30:55–63. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Totzeck M, Mincu RI, Heusch G and Rassaf
T: Heart failure from cancer therapy: Can we prevent it? ESC Heart
Fail. 6:856–862. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Hadi N, Yousif NG, Al-amran FG, Huntei NK,
Mohammad BI and Ali SJ: Vitamin E and telmisartan attenuates
doxorubicin induced cardiac injury in rat through down regulation
of inflammatory response. BMC Cardiovasc Disord. 12:632012.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Yamanaka S, Tatsumi T, Shiraishi J, Mano
A, Keira N, Matoba S, Asayama J, Fushiki S, Fliss H and Nakagawa M:
Amlodipine inhibits doxorubicin-induced apoptosis in neonatal rat
cardiac myocytes. J Am Coll Cardiol. 41:870–878. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Cardinale D, Colombo A, Lamantia G,
Colombo N, Civelli M, De Giacomi G, Rubino M, Veglia F, Fiorentini
C and Cipolla CM: Anthracycline-induced cardiomyopathy: Clinical
relevance and response to pharmacologic therapy. J Am Coll Cardiol.
55:213–220. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Plana JC, Galderisi M, Barac A, Ewer MS,
Ky B, Scherrer-Crosbie M, Ganame J, Sebag IA, Agler DA, Badano LP,
et al: Expert consensus for multimodality imaging evaluation of
adult patients during and after cancer therapy: A report from the
American society of echocardiography and the european association
of cardiovascular imaging. J Am Soc Echocardiogr. 27:911–939. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Cappetta D, Esposito G, Coppini R, Piegari
E, Russo R, Ciuffreda LP, Rivellino A, Santini L, Rafaniello C,
Scavone C, et al: Effects of ranolazine in a model of
doxorubicin-induced left ventricle diastolic dysfunction. Br J
Pharmacol. 174:3696–3712. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Henriksen PA: Anthracycline
cardiotoxicity: An update on mechanisms, monitoring and prevention.
Heart. 104:971–977. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Aminkeng F, Ross CJ, Rassekh SR, Hwang S,
Rieder MJ, Bhavsar AP, Smith A, Sanatani S, Gelmon KA, Bernstein D,
et al: Recommendations for genetic testing to reduce the incidence
of anthracycline-induced cardiotoxicity. Br J Clin Pharmacol.
82:683–695. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Nair AB and Jacob S: A simple practice
guide for dose conversion between animals and human. J Basic Clin
Pharm. 7:27–31. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Neilan TG, Jassal DS, Scully MF, Chen G,
Deflandre C, McAllister H, Kay E, Austin SC, Halpern EF, Harmey JH
and Fitzgerald DJ: Iloprost attenuates doxorubicin-induced cardiac
injury in a murine model without compromising tumour suppression.
Eur Heart J. 27:1251–1256. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Jenkins GR, Lee T, Moland CL, Vijay V,
Herman EH, Lewis SM, Davis KJ, Muskhelishvili L, Kerr S, Fucoe JC
and Desai VG: Sex-related differential susceptibility to
doxorubicin-induced cardiotoxicity in B6C3F1 mice.
Toxicol Appl Pharmacol. 310:159–174. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Vijay V, Moland CL, Han T, Fuscoe JC, Lee
T, Herman EH, Jenkins GR, Lewis SM, Cummings CA, Gao Y, et al:
Early transcriptional changes in cardiac mitochondria during
chronic doxorubicin exposure and mitigation by dexrazoxane in mice.
Toxicol Appl Pharmacol. 295:68–84. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Kanno S, Ishikawa M, Takayanagi M,
Takayanagi Y and Sasaki K: Potentiation of acetaminophen
hepatotoxicity and mortality by doxapram in mice. Biol Pharm Bull.
21:934–937. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Kanno S, Tomizawa A, Hiura T, Osanai Y,
Kakuta M, Kitajima Y, Koiwai K, Ohtake T, Ujibe M and Ishikawa M:
Melatonin protects on toxicity by acetaminophen but not on
pharmacological effects in mice. Biol Pharm Bull. 29:472–476. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Blankenberg FG, Tait JF and Strauss HW:
Apoptotic cell death: Its implications for imaging in the next
millennium. Eur J Nucl Med. 27:359–367. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Bennink RJ, van den Hoff MJ, van Hemert
FJ, de Bruin KM, Spijkerboer AL, Vanderheyden JL, Steinmetz N and
van Eck-Smit BL: Annexin V imaging of acute doxorubicin
cardiotoxicity (apoptosis) in rats. J Nucl Med. 45:842–848.
2004.PubMed/NCBI
|
|
27
|
Schwartz RG, Jain D and Storozynsky E:
Traditional and novel methods to assess and prevent
chemotherapy-related cardiac dysfunction noninvasively. J Nucl
Cardiol. 20:443–464. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Salvesen GS and Dixit VM: Caspases:
Intracellular signaling by proteolysis. Cell. 91:443–446. 1997.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
He H, Liu C, Wu Y, Zhang X, Fan J and Cao
Y: A multiscale physiologically-based pharmacokinetic model for
doxorubicin to explore its mechanisms of cytotoxicity and
cardiotoxicity in human physiological contexts. Pharm Res.
35:1742018. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Eppstein DA, Kurahara CG, Bruno NA and
Terrell TG: Prevention of doxorubicin-induced hematotoxicity in
mice by interleukin 1. Cancer Res. 49:3955–3960. 1989.PubMed/NCBI
|
|
31
|
Li K, Sung RY, Huang WZ, Yang M, Pong NH,
Lee SM, Chan WY, Zhao H, To MY, Fok TF, et al: Thrombopoietin
protects against in vitro and in vivo cardiotoxicity induced by
doxorubicin. Circulation. 113:2211–2220. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Liu X, Chen Z, Chua CC, Ma YS, Youngberg
GA, Hamdy R and Chua BH: Melatonin as an effective protector
against doxorubicin-induced cardiotoxicity. Am J Physiol Heart Circ
Physiol. 283:H254–H263. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Montgomery MD, Chan T, Swigart PM, Myagmar
BE, Dash R and Simpson PC: An alpha-1A adrenergic receptor agonist
prevents acute doxorubicin cardiomyopathy in male mice. PLoS One.
12:e01684092017. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Dawn B, Xuan YT, Guo Y, Rezazadeh A, Stein
AB, Hunt G, Wu WJ, Tan W and Bolli R: IL-6 plays an obligatory role
in late preconditioning via JAK-STAT signaling and upregulation of
iNOS and COX-2. Cardiovasc Res. 64:61–71. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
McGinnis GR, Ballmann C, Peters B,
Nanayakkara G, Roberts M, Amin R and Quindry JC: Interleukin-6
mediates exercise preconditioning against myocardial ischemia
reperfusion injury. Am J Physiol Heart Circ Physiol.
308:H1423–H1433. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Nishimura H, Okazaki T, Tanaka Y, Nakatani
K, Hara M, Matsumori A, Sasayama S, Mizoguchi A, Hiai H, Minato N
and Honjo T: Autoimmune dilated cardiomyopathy in PD-1
receptor-deficient mice. Science. 291:319–322. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Okazaki T, Tanaka Y, Nishio R, Mitsuiye T,
Mizoguchi A, Wang J, Ishida M, Hiai H, Matsumori A, Minato N and
Honjo T: Autoantibodies against cardiac troponin I are responsible
for dilated cardiomyopathy in PD-1-deficient mice. Nat Med.
9:1477–1483. 2003. View
Article : Google Scholar : PubMed/NCBI
|
|
38
|
Qin XH, Lee VW, Wang YP, Zheng GP, Wang Y,
Alexander SI and Harris DC: A protective role for programmed death
1 in progression of murine adriamycin nephropathy. Kidney Int.
70:1244–1250. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Smart N, Mojet MH, Latchman DS, Marber MS,
Duchen MR and Heads RJ: IL-6 induces PI 3-kinase and nitric
oxide-dependent protection and preserves mitochondrial function in
cardiomyocytes. Cardiovasc Res. 69:164–177. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Sheng CC, Amiri-Kordestani L, Palmby T,
Force T, Hong CC, Wu JC, Croce K, Kim G and Moslehi J: 21st Century
cardio-oncology: Identifying cardiac safety signals in the era of
personalized medicine. JACC Basic Transl Sci. 1:386–398. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Zhang YW, Shi J, Li YJ and Wei L:
Cardiomyocyte death in doxorubicin-induced cardiotoxicity. Arch
Immunol Ther Exp (Warsz). 57:435–445. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Lipshultz SE, Colan SD, Gelber RD,
Perez-Atayde AR, Sallan SE and Sanders SP: Late cardiac effects of
doxorubicin therapy for acute lymphoblastic leukemia in childhood.
N Engl J Med. 324:808–815. 1991. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Tsutamoto T, Hisanaga T, Wada A, Maeda K,
Ohnishi M, Fukai D, Mabuchi N, Sawaki M and Kinoshita M:
Interleukin-6 spillover in the peripheral circulation increases
with the severity of heart failure, and the high plasma level of
interleukin-6 is an important prognostic predictor in patients with
congestive heart failure. J Am Coll Cardiol. 31:391–398. 1998.
View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Gwechenberger M, Mendoza LH, Youker KA,
Frangogiannis NG, Smith CW, Michael LH and Entman ML: Cardiac
myocytes produce interleukin-6 in culture and in viable border zone
of reperfused infarctions. Circulation. 99:546–551. 1999.
View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Sun Y: Oxidative stress and cardiac
repair/remodeling following infarction. Am J Med Sci. 334:197–205.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Neri M, Fineschi V, Di Paolo M, Pomara C,
Riezzo I, Turillazzi E and Cerretani D: Cardiac oxidative stress
and inflammatory cytokines response after myocardial infarction.
Curr Vasc Pharmacol. 13:26–36. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Li JY, He Y, Ke HH, Jin Y, Jiang ZY and
Zhong GQ: Plasma oxidative stress and inflammatory biomarkers are
associated with the sizes of the left atrium and pulmonary vein in
atrial fibrillation patients. Clin Cardiol. 40:89–94. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Hartman MHT, Groot HE, Leach IM, Karper JC
and van der Harst P: Translational overview of cytokine inhibition
in acute myocardial infarction and chronic heart failure. Trends
Cardiovasc Med. 28:369–379. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Okazaki T, Maeda A, Nishimura H, Kurosaki
T and Honjo T: PD-1 immunoreceptor inhibits B cell
receptor-mediated signaling by recruiting src homology
2-domain-containing tyrosine phosphatase 2 to phosphotyrosine. Proc
Natl Acad Sci USA. 98:13866–13871. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Berthiaume JM and Wallace KB: Persistent
alterations to the gene expression profile of the heart subsequent
to chronic doxorubicin treatment. Cardiovasc Toxicol. 7:178–191.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Holmgren G, Synnergren J, Bogestål Y,
Améen C, Åkesson K, Holmgren S, Lindahl A and Sartipy P:
Identification of novel biomarkers for doxorubicin-induced toxicity
in human cardiomyocytes derived from pluripotent stem cells.
Toxicology. 328:102–111. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Thompson KL, Rosenzweig BA, Zhang J,
Knapton AD, Honchel R, Lipshultz SE, Retief J, Sistare FD and
Herman EH: Early alterations in heart gene expression profiles
associated with doxorubicin cardiotoxicity in rats. Cancer
Chemother Pharmacol. 66:303–314. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Todorova VK, Beggs ML, Delongchamp RR,
Dhakal I, Makhoul I, Wei JY and Klimberg VS: Transcriptome
profiling of peripheral blood cells identifies potential biomarkers
for doxorubicin cardiotoxicity in a rat model. PLoS One.
7:e483982012. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Yi X, Bekeredjian R, DeFilippis NJ,
Siddiquee Z, Fernandez E and Shohet RV: Transcriptional analysis of
doxorubicin-induced cardiotoxicity. Am J Physiol Heart Circ
Physiol. 290:H1098–H1102. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Zhao WJ, Wei SN, Zeng XJ, Xia YL, Du J and
Li HH: Gene expression profiling identifies the novel role of
immunoproteasome in doxorubicin-induced cardiotoxicity. Toxicology.
333:76–88. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Bertinchant JP, Polge A, Juan JM,
Oliva-Lauraire MC, Giuliani I, Marty-Double C, Burdy JY,
Fabbro-Peray P, Laprade M, Bali JP, et al: Evaluation of cardiac
troponin I and T levels as markers of myocardial damage in
doxorubicin-induced cardiomyopathy rats, and their relationship
with echocardiographic and histological findings. Clin Chim Acta.
329:39–51. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Shan K, Lincoff AM and Young JB:
Anthracycline-induced cardiotoxicity. Ann Intern Med. 125:47–58.
1996. View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Gharib MI and Burnett AK:
Chemotherapy-induced cardiotoxicity: Current practice and prospects
of prophylaxis. Eur J Heart Fail. 4:235–242. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Ganatra S, Nohria A, Shah S, Groarke JD,
Sharma A, Venesy D, Patten R, Gunturu K, Zarwan C, Neilan TG, et
al: Upfront dexrazoxane for the reduction of anthracycline-induced
cardiotoxicity in adults with preexisting cardiomyopathy and
cancer: A consecutive case series. Cardiooncology.
5:12019.PubMed/NCBI
|
|
60
|
Langer SW: Dexrazoxane for the treatment
of chemotherapy-related side effects. Cancer Manag Res. 6:357–363.
2014. View Article : Google Scholar : PubMed/NCBI
|
